Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer

J. N. Ingle, D. L. Ahmann, S. J. Green, J. H. Edmonson, E. T. Creagan, R. G. Hahn, J. Rubin

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Fifty-five women with progressive metastatic breast cancer who were paramenopausal (1 to <5 years since last menstrual period) or castrated were randomized to receive either megestrol acetate (150 mg/m2 daily in three divided doses) or tamoxifen (10 mg twice daily). The regression rate (complete plus partial) was higher for tamoxifen (26%) than for megestrol acetate (14%), but not significantly so. Analysis of time to treatment failure showed no significant difference (medians: megestrol acetate, 65 days; tamoxifen, 58 days). There was a survival advantage associated with megestrol acetate (P = 0.02 after adjustment for stratification factors) that is difficult to interpret given the results of analysis of regression and time to treatment failure for the two agents.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume5
Issue number2
StatePublished - 1982

Fingerprint

Megestrol Acetate
Tamoxifen
Randomized Controlled Trials
Breast Neoplasms
Treatment Failure
Regression Analysis
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J. H., Creagan, E. T., Hahn, R. G., & Rubin, J. (1982). Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 5(2), 155-160.

Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. / Ingle, J. N.; Ahmann, D. L.; Green, S. J.; Edmonson, J. H.; Creagan, E. T.; Hahn, R. G.; Rubin, J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 5, No. 2, 1982, p. 155-160.

Research output: Contribution to journalArticle

Ingle, J. N. ; Ahmann, D. L. ; Green, S. J. ; Edmonson, J. H. ; Creagan, E. T. ; Hahn, R. G. ; Rubin, J. / Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1982 ; Vol. 5, No. 2. pp. 155-160.
@article{1f79887a5fea433a96d80c7facab0b68,
title = "Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer",
abstract = "Fifty-five women with progressive metastatic breast cancer who were paramenopausal (1 to <5 years since last menstrual period) or castrated were randomized to receive either megestrol acetate (150 mg/m2 daily in three divided doses) or tamoxifen (10 mg twice daily). The regression rate (complete plus partial) was higher for tamoxifen (26{\%}) than for megestrol acetate (14{\%}), but not significantly so. Analysis of time to treatment failure showed no significant difference (medians: megestrol acetate, 65 days; tamoxifen, 58 days). There was a survival advantage associated with megestrol acetate (P = 0.02 after adjustment for stratification factors) that is difficult to interpret given the results of analysis of regression and time to treatment failure for the two agents.",
author = "Ingle, {J. N.} and Ahmann, {D. L.} and Green, {S. J.} and Edmonson, {J. H.} and Creagan, {E. T.} and Hahn, {R. G.} and J. Rubin",
year = "1982",
language = "English (US)",
volume = "5",
pages = "155--160",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer

AU - Ingle, J. N.

AU - Ahmann, D. L.

AU - Green, S. J.

AU - Edmonson, J. H.

AU - Creagan, E. T.

AU - Hahn, R. G.

AU - Rubin, J.

PY - 1982

Y1 - 1982

N2 - Fifty-five women with progressive metastatic breast cancer who were paramenopausal (1 to <5 years since last menstrual period) or castrated were randomized to receive either megestrol acetate (150 mg/m2 daily in three divided doses) or tamoxifen (10 mg twice daily). The regression rate (complete plus partial) was higher for tamoxifen (26%) than for megestrol acetate (14%), but not significantly so. Analysis of time to treatment failure showed no significant difference (medians: megestrol acetate, 65 days; tamoxifen, 58 days). There was a survival advantage associated with megestrol acetate (P = 0.02 after adjustment for stratification factors) that is difficult to interpret given the results of analysis of regression and time to treatment failure for the two agents.

AB - Fifty-five women with progressive metastatic breast cancer who were paramenopausal (1 to <5 years since last menstrual period) or castrated were randomized to receive either megestrol acetate (150 mg/m2 daily in three divided doses) or tamoxifen (10 mg twice daily). The regression rate (complete plus partial) was higher for tamoxifen (26%) than for megestrol acetate (14%), but not significantly so. Analysis of time to treatment failure showed no significant difference (medians: megestrol acetate, 65 days; tamoxifen, 58 days). There was a survival advantage associated with megestrol acetate (P = 0.02 after adjustment for stratification factors) that is difficult to interpret given the results of analysis of regression and time to treatment failure for the two agents.

UR - http://www.scopus.com/inward/record.url?scp=0020472669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020472669&partnerID=8YFLogxK

M3 - Article

C2 - 7046412

AN - SCOPUS:0020472669

VL - 5

SP - 155

EP - 160

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 2

ER -